FSTL3 and hepatocellular carcinoma: In conclusion, the enhanced expression of INHA or INHBB detected in 80% of our HCC patients may serve as alternative or additional regulators besides follistatin, fstl3 and cripto, overriding the antiproliferative and proapoptotic action of activin A.